Eikon Therapeutics Inc（EIKN）資訊與事件EIKNEikon Therapeutics Inc

Eikon Therapeutics Updates EIK1001 Data at 2026 ESMO Congress

Eikon Therapeutics announced the presentation of updated data for EIK1001 at the 2026 European Society for Medical Oncology Congress in Madrid, Spain. "These updated results presented at ESMO from the squamous NSCLC cohort build on the mature non-squamous cohort data presented at ASCO and further support the potential of adding EIK1001 to pembrolizumab and chemotherapy," said Roy Baynes, M.D., Ph.D., Chief Medical Officer of Eikon. "The observed response and disease control rates, as well as a 12.9-month median duration of response, are encouraging, with several patients remaining in active follow-up. These findings support continued evaluation of this combination for patients with advanced NSCLC." Updated data from the open-label TeLuRide-005 trial evaluating TLR7/8 dual-agonist EIK1001 in combination with both pembrolizumab and histology-appropriate chemotherapy in participants with advanced NSCLC demonstrates potentially durable effect of EIK1001 in combination with standard of care, as well as a tolerability profile supportive of systemic administration in an outpatient setting, a potential key differentiator of EIK1001 from previous TLR7/8 targeted therapies. In TeLuRide-005, 72 participants with previously untreated stage 4 NSCLC received intravenous EIK1001 once-weekly combined with standard of care pembrolizumab plus histology-appropriate chemotherapy once every third week. After 8 cycles, EIK1001 administration was reduced to Q3W. The maximum treatment duration is 2 years for EIK1001 in combination with pembrolizumab, with pemetrexed continued at the discretion of the Investigator for non-squamous participants. At the July 13, 2026, safety data cutoff, among the safety evaluable population, the combination of EIK1001 with pembrolizumab and chemotherapy was generally well tolerated, with an adverse event profile similar to standard-of-care alone. Grade 3 or higher treatment-related adverse events occurred in 48.6% of participants, and TRAEs led to treatment discontinuation in 6.9%. The most common Grade 3 or higher TRAEs were neutropenia, anemia, and thrombocytopenia. Cytokine release syndrome events were all low-grade, and there were no Grade 3 or higher events. There were no TRAEs that led to death. This profile was sufficient to support administration in an outpatient setting during the ongoing trial. Among the efficacy-evaluable population, EIK1001 treatment in combination with pembrolizumab and chemotherapy pooled data with a median follow-up of 17.2 months resulted in a 63.1% objective response rate and 89.2% disease control rate at the efficacy data cutoff of October 1, 2026. Objective responses were observed across all PD-L1 tumor proportion score subgroups. Among participants in the squamous cohort, an ORR of 72.4% and a DCR of 100% were observed, respectively, with a median follow-up of 12.7 months and a median duration of response of 12.9 months at the efficacy data cutoff. Among participants in the non-squamous cohort, an ORR of 55.6% and a DCR of 80.6% were observed, respectively, with a median follow-up of 17.9 months. The median DOR in the non-squamous cohort was 11.2 months at the efficacy data cutoff. In addition to the TeLuRide-005 data presented at ESMO, Eikon is currently conducting a Phase 2/3 registrational trial of EIK1001 in combination with pembrolizumab and histology-appropriate chemotherapy in systemic therapy-naive participants with stage 4 non-squamous or squamous NSCLC, also known as TeLuRide-008. Eikon expects to conduct a first interim analysis to select the single dose of EIK1001 to take forward for the remainder of this trial in the second half of 2027.

Eikon Therapeutics to Present Four Clinical Candidates at 2026 ESMO Congress

Eikon Therapeutics announced the publication of full-text abstracts from its four clinical candidates to be presented at the 2026 European Society for Medical Oncology, ESMO, Congress in Madrid, Spain beginning on October 23, 2026. Presentations to cover updates across Eikon's clinical pipeline including: Updated data from TeLuRide-005, an ongoing open-label Phase 2 trial of EIK1001, a TLR7/8 dual-agonist, plus pembrolizumab and histology-appropriate chemotherapy in stage 4 non-small cell lung cancer; Updated cohort data from an ongoing Phase 1/2 study of EIK1003, a highly selective non-brain penetrant PARP1 inhibitor, as monotherapy and in combination with chemotherapy in advanced solid tumors; Initial data from a Phase 1/2 study of EIK1003 in combination with the novel hormonal agent abiraterone in metastatic prostate cancer; Initial results from an ongoing Phase 1/2 study of EIK1004, a highly selective CNS-penetrant PARP1 inhibitor in advanced solid malignancies; Preliminary safety, tolerability and pharmacokinetic data for EIK1005, a Werner helicase inhibitor.

Eikon Therapeutics Submits IND Application for EIK1006 to FDA

Eikon Therapeutics announced the submission of an Investigational New Drug, or IND, application to the FDA to evaluate EIK1006 for the treatment of advanced metastatic prostate cancer. EIK1006 is a novel androgen receptor antagonist that is structurally unrelated to currently available lutamide-class antagonists.